How ActivMix Technology Enhances CO2 Removal in the Hemolung RAS

16 October 2015 White Papers

By ALung Technologies, Inc. The Hemolung Respiratory Assist System (RAS) is the only extracorporeal CO2 removal system that has been specifically designed to provide the safest, simplest and most efficient ECCO2R therapy. Other systems are non-integrated, modified ECMO or dialysis arrangements, and as such, have neither the level of safety, simplicity, nor efficiency of the (read more)

Dr. Jeremy Kimmel Featured on Regenerative Medicine Today podcast

11 August 2015 Recent News

Dr. Jeremy Kimmel, ALung’s Director of New Technology, was recently featured as a guest on the “Regenerative Medicine Today” podcast where he discussed Respiratory Dialysis with the Hemolung RAS. Listen to learn: How does Respiratory Dialysis work? What are the benefits of Respiratory Dialysis? The history of ALung Technologies What is the future of extracorporeal (read more)

New Publications Show Promise of Improved Artificial Lung Devices

3 August 2015 Press Release, Recent News

Technology developed at the University of Pittsburgh and licensed by ALung enhances the performance of artificial lung devices, paving the way for the development of less invasive respiratory support systems. Pittsburgh, PA (August 3, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute (read more)

ALung Receives CE Mark for New Hemolung XG4 Cartridge and Catheter Kits

18 June 2015 Press Release, Recent News

The new Hemolung XG4 Cartridge and Catheter Kits further simplify initiation of Respiratory Dialysis®. Pittsburgh, PA (June 18, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received CE mark approval for its next generation Hemolung (read more)

Case series of protective ventilation for ARDS using partial extracorporeal CO2 removal

Rauch S.1, Roth H.2, Deininger T.2, Kuhwald A.2, Lund L.3, Fischer M.1 1ALB FILS KLINIKEN, Anesthesiology, Göppingen, Germany, 2ALB FILS KLINIKEN, Internal Medicine, Göppingen, Germany, 3ALung Technologies Inc., Pittsburgh, United States Poster presentation from the EuroELSO 2015 4th International Congress Objectives In the ARDS Network trial of low tidal volume ventilation, hypercapnia and respiratory acidosis (read more)

A retrospective observational case series of low flow veno-venous extracorporeal carbon dioxide removal use in patients with respiratory failure

Moss C.E., Galtrey E., Gillon S., Langrish C., Meadows C., Wyncoll D., Ioannou N., Camporota L., Tricklebank S., Daly K., Evans S., Ong D., Sanderson B., Waldie J., Dando R., Elliott-Hammond C., Lozinski M., Nichols H., Barrett N. Department of Critical Care, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom Poster presentation from the (read more)

ALung Appoints David Motley to its Board of Directors

9 April 2015 Press Release

PITTSBURGH, PA (April 9, 2015) – ALung Technologies, the leading provider of low-flow extracorporeal CO2 removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the appointment of David L. Motley to the Company’s Board of Directors. Mr. Motley was elected to the Board at the Company’s annual shareholder meeting held on March 26, (read more)

University of Maryland Second in USA to use Hemolung RAS

Hemolung RAS used under emergency use rules to facilitate extubation and lung recovery in a patient with COPD due to alpha-1 antitrypsin deficiency. (read more)

ALung Launches Next Generation Extracorporeal CO2 Removal System

12 February 2015 Press Release

New Hemolung CR4 Controller provides unparalleled features and simplicity. The Hemolung CR4 Controller, part of the Hemolung Respiratory Assist System, provides extracorporeal carbon dioxide removal (ECCO2R) for patients suffering from acute respiratory failure.  Pittsburgh, PA (February 12, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients (read more)

ALung Receives Marketing Clearance for Hemolung RAS in Australia

14 January 2015 Press Release

Partners with Medtel Australia as Distributor Pittsburgh, PA (January 14, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received marketing clearance from the Australian Therapeutic Goods Administration (TGA) for its Hemolung Respiratory Assist System (RAS). (read more)